دورية أكاديمية
أعرض في EDS

Effects of Yangxinshi tablet on exercise tolerance in patients with coronary heart disease: A protocol of randomized, double-blind, placebo-controlled, and multi-center trial.

التفاصيل البيبلوغرافية
العنوان: Effects of Yangxinshi tablet on exercise tolerance in patients with coronary heart disease: A protocol of randomized, double-blind, placebo-controlled, and multi-center trial.
المؤلفون: Zhang S; Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province., Liang C; Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province., Yang Y; Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province., Zhao Z; Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province., Li J; Operating Room Department, Feicheng Mining Bureau Central Hospital, Tai'an City, Shandong Province, China., Meng X; Cardiovascular and Cardiac Rehabilitation Department, First Affiliated Hospital of Changchun Chinese Medicine University, Changchun City, Jilin Province.
المصدر: Medicine [Medicine (Baltimore)] 2020 Jul 31; Vol. 99 (31), pp. e21485.
نوع المنشور: Clinical Trial Protocol; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Coronary Disease*/physiopathology , Coronary Disease*/therapy , Drugs, Chinese Herbal*/administration & dosage , Exercise Tolerance*/drug effects , Medicine, Chinese Traditional*/methods, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; China ; Double-Blind Method ; Exercise Test ; Quality of Life ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Walk Test ; Multicenter Studies as Topic
مستخلص: Background: Exercise intolerance is very common in patients with coronary heart disease (CHD). Although some researches confirming the validation of traditional Chinese medicine (TCM) on CHD treatment, the effect of TCM on improving the exercise tolerance of patients with CHD remains unclear so far. Our trial is to investigate whether the Yangxinshi (YXS) tablet can improve exercise tolerance as well as the quality of life among CHD patients.
Methods: It is a randomized, double-blind, placebo-controlled, multi-center trial. A total of 90 patients with CHD from 3 hospitals in China will be enrolled and randomly assigned to one of 2 groups: YXS group, N = 45; placebo group, N = 45. The 2 groups will simultaneously receive standardized western medicine and exercise-based cardiac rehabilitation program for 12 weeks. The primary outcome measure is the exercise capacity, which will be evaluated by the cardiopulmonary exercise test and 6-minute walking test. The 2nd outcomes include symptom improvement, psychologic issues, laboratory tests, side effects, and adverse events.
Discussion: To our knowledge, it is the 1st randomized controlled trial to evaluate the effect of TCM YXS tablet on exercise tolerance in patients with CHD. The results will provide more evidence for future studies in this area.
Trial Registration: This study protocol was registered in Research Registry (researchregistry5752).
References: Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–71.
Salvi S. Faculty Opinions recommendation of Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2016. doi: 10.3410/f.725286838.793523287.
Kaur K, Bedi G, Kaur M, et al. Lipid peroxidation and the levels of antioxidant enzymes in coronary artery disease. Indian J Clin Biochem 2008;23:33–7.
Chen WW, Gao RL, Liu LS, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol 2017;14:1–0.
Wu Y, Benjamin EJ, Macmahon S. Prevention and control of cardiovascular disease in the rapidly changing economy of China. Circulation 2016;133:2545–60.
Kelly BB, Narula J, Fuster V. Recognizing Global Burden of Cardiovascular Disease and Related Chronic Diseases. Mt Sinai J Med 2012;79:632–40.
Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793–801. doi: 10.1056/NEJMoa011858. (PMID: 10.1056/NEJMoa011858)
Kokkinos P, Myers J. Exercise and physical activity. Circulation 2010;122:1637–48.
Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol 2016;67:1–2.
Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation 2004;109:1371–8.
Keteyian SJ, Brawner CA, Savage PD, et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 2008;156:292–300.
Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation 2011;124:2458–73.
Qiao Y, Zhang J, Liu Y, et al. Efficacy and safety of zhenyuan capsule for coronary heart disease with abnormal glucose and lipid metabolism: study protocol for a randomized, double-blind, parallel-controlled, multicenter clinical trial. Evid Based Complement Alternat Med 2018;2018:1–7.
Wang D, Calabrese EJ, Lian B, et al. Hormesis as a mechanistic approach to understanding herbal treatments in traditional Chinese medicine. Pharmacol Ther 2018;184:42–50.
Du H, Zhang H, Zhao Y, et al. Metabolic analysis of the antidepressive effects of Yangxinshi tablet in a vascular depression model in mice. Biomed Chromatogr 2017;32:.
Zhang C, Mi Z, Tian W, et al. Clinical observation on therapeutic effect of clopidogrel bisulfate tablets combined with atorvastatin calcium capsules and Yangxinshi tablets on 78 cases of angina pectoris after PCI. World Chin Med 2014;9:1299–2130.
Agha RA, Altman DG, Rosin D. The SPIRIT 2013 statement – defining standard protocol items for trials. Inter J Surg 2015;13:288–91.
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. Circulation 2011;124:2574–609.
Montalescot G, Sechtem U, et al. Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–7.
Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428–46.
Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333–41.
Maier W, Buller R, Philipp M, et al. The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988;14:61–8.
Hamilton M. The Hamilton rating scale for depression. Assessment of Depression 1986;143–52. doi: 10.1007/978-3-642-70486-4_14. (PMID: 10.1007/978-3-642-70486-4_14)
Zhu J, Yi X, Zhang J, et al. Chemical profiling and antioxidant evaluation of Yangxinshi Tablet by HPLC–ESI-Q-TOF-MS/MS combined with DPPH assay. J Chromatogr B 2017;1060:262–71.
Piepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1–7.
Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. Scand J Med Sci Sports 2010;20:545–55.
Colevas AD, Setser A. The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004;22:6098–16098.
Zhang Z-H, Chen H, Vaziri ND, et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J Proteome Res 2016;15:3802–12.
Wang J. Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine. Int Med Open Access 2012;2:03.
Wang J, Xiong X. Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med 2012;2012:1–1.
Stanley WC. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Ther 2004;9:31–45.
Zhang H, Zhao Y, Xia Z, et al. Metabolic profiles revealed anti-ischemia-reperfusion injury of Yangxinshi tablet in rats. J Ethnopharmacol 2018;214:124–33.
Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007;120:799–806.
Cho C, Lee C, Kim M, et al. Effects of cardiac rehabilitation on health-related quality of life in patients with cardiovascular disease. Asian J Human Serv 2016;11:111–23.
Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review. Int J Nurs Stud 2012;49:755–71.
المشرفين على المادة: 0 (Drugs, Chinese Herbal)
0 (Yangxinshi)
تواريخ الأحداث: Date Created: 20200807 Date Completed: 20200824 Latest Revision: 20240329
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC7402915
DOI: 10.1097/MD.0000000000021485
PMID: 32756176
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000021485